13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

1242 trials found

diseases per page:

Showing 1 to 10 of 1,242 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04880577 (ClinicalTrials.gov)	September 15, 2022	30/4/2021	Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple ...	Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple ...	Multiple Sclerosis, Relapsing-Remitting;Fatigue	Drug: TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY];Drug: Placebo	Harvard Medical School	Gilead Sciences	Not yet recruiting	18 Years	N/A	All	60	Phase 2	NULL
2	NCT05285891 (ClinicalTrials.gov)	April 30, 2022	8/3/2022	Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis	Randomized, Blinded Discontinuation Trial of Ocrelizumab in Early Relapsing Multiple Sclerosis (AMS0 ...	Multiple Sclerosis	Biological: Ocrelizumab;Drug: Placebo for Ocrelizumab	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence (ACE)	Not yet recruiting	18 Years	55 Years	All	175	Phase 4	NULL
3	EUCTR2021-003772-14-HR (EUCTR)	11/03/2022	14/03/2022	A Study to Evaluate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis	A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TOINVESTIGATE THE EFFICACY OF FENEBRUTINIB IN RE ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: Fenebrutinib Product Code: RO7010939 INN or Proposed INN: FENEBRUTINIB Other descriptive ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	102	Phase 2	Serbia;Egypt;Czechia;Slovenia;Slovakia;Morocco;Kenya;Croatia;Norway;Japan
4	EUCTR2021-000048-23-DE (EUCTR)	03/03/2022	07/10/2021	Study to test IMU-838 in patients with progressive multiple sclerosis	Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and To ...	Progressive forms of Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10053395; ...	Product Name: IMU-838 INN or Proposed INN: Vidofludimus calcium Other descriptive name: IM90838 Product ...	Immunic AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 2	United States;Serbia;Czechia;Finland;Ukraine;North Macedonia;Russian Federation;Hungary;Canada;Polan ...
5	NCT05269628 (ClinicalTrials.gov)	March 2022	13/2/2022	Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype	Mechanisms of Cannabidiol (CBD) in Persons With Multiple Sclerosis (MS): the Role of Sleep and Pain ...	Multiple Sclerosis;Sleep;Pain	Drug: Cannabidiol (CBD);Drug: Tetrahydrocannabinol (THC);Drug: Placebo CBD;Drug: Placebo THC	Tiffany J. Braley, MD, MS	National Center for Complementary and Integrative Health (NCCIH)	Not yet recruiting	18 Years	65 Years	All	166	Phase 2	United States
6	NCT05145361 (ClinicalTrials.gov)	February 28, 2022	21/11/2021	Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)	A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics a ...	NMO Spectrum Disorder	Drug: B001 injection;Biological: Placebo	Shanghai Pharmaceuticals Holding Co., Ltd	NULL	Not yet recruiting	18 Years	70 Years	All	45	Early Phase 1	China
7	NCT04877457 (ClinicalTrials.gov)	February 15, 2022	30/4/2021	Ocrelizuamb for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated D ...	A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of ...	Radiologically Isolated Syndrome;Multiple Sclerosis	Drug: Ocrelizumab;Other: Placebo	Yale University	Genentech, Inc.	Recruiting	18 Years	40 Years	All	100	Phase 4	United States
8	EUCTR2021-000048-23-NL (EUCTR)	10/02/2022	12/10/2021	Study to test IMU-838 in patients with progressive multiple sclerosis	Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and To ...	Progressive forms of Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10053395; ...	Product Name: IMU-838 INN or Proposed INN: Vidofludimus calcium Other descriptive name: IM90838 Product ...	Immunic AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 2	Serbia;United States;Czechia;Finland;Ukraine;North Macedonia;Russian Federation;Hungary;Canada;Polan ...
9	NCT05123703 (ClinicalTrials.gov)	February 4, 2022	16/11/2021	A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And ...	A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study To Evaluate Safety And Efficac ...	Relapsing-Remitting Multiple Sclerosis	Drug: Ocrelizumab;Other: Ocrelizumab Placebo;Drug: Fingolimod;Other: Fingolimod Placebo	Hoffmann-La Roche	PPD	Recruiting	10 Years	17 Years	All	233	Phase 3	United States;Argentina;Spain;Ukraine;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Germa ...
10	NCT05119569 (ClinicalTrials.gov)	January 28, 2022	29/10/2021	A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)	A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in ...	Relapsing Multiple Sclerosis	Drug: fenebrutinib;Drug: placebo	Hoffmann-La Roche	NULL	Not yet recruiting	18 Years	55 Years	All	102	Phase 2	NULL

First Previous1 2 3 4 5…125Next Last